Genetic predisposition in cutaneous melanoma;Predisposición genética en el melanoma cutáneo

Actas Dermo-Sifiliograficas

Volumn 97, Issue 4, 2006, Pages 229-240

  Avilés, José A ^a   Lázaro, Pablo ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Genetics; Melanoma; Prevalence

Indexed keywords

MELANOCORTIN 1 RECEPTOR; PROTEIN P16;

CANCER RISK; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HEREDITY; HUMAN; INCIDENCE; MEDICAL RESEARCH; MELANOCYTE; MELANOMA; PENETRANCE; POPULATION GENETICS; PREVALENCE; REVIEW; SKIN PIGMENTATION; ULTRAVIOLET RADIATION;

EID: 33745684011     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73390-7     Document Type: Review

References (87)

1. Parkin M, Pisani P, Ferlay J. Estimates o the worlwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;79:827-41.
2. Jones WO, Harman CR, Ng AK, Shaw JH. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg. 1999;23:732-5.
3. Setlow RB, Grist E, Thompson K, Woodhead AD. Wavelenghs effective in induction of malignant melanoma. Proc Natl Acad Sci USA. 1993;90:6666-70.
4. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124:869-71.
5. Prota G. Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. Pigment Cell Res. 2000;13:283-93.
6. Sturm RA, Box NF, Ramsay M. Human pigmentation genetics: the difference is only skin deep. Bioessays. 1998;20:712-21.
7. Orlow JS. The biogenesis of melanosomas. En: Nordund LL, Boissy RE, Hearing VJ, King RA, Ortonne JP, editors. The pigmentary system: physiology and pathophysiology. New York: Oxford University Press; 1998. p. 97-106.
8. Yamamoto O, Bhawan J. Three modes of melanosome transfers in Caucasian facial skin: hipótesis based on an ultrastructural study. Pigment Cell Res. 1994;7:158-69.
9. Xu X, Thornwal M, Lundin LG, Chhajlani V. Val92Met variant of the melanocyte stimulating hormone receptor gene. Nat Genet. 1996;14:384.
10. Hunt G, Kyne S, Wakamatsu K, Ito S, thody AJ. Nle4Dphe7 alpha-melanocyte-stimulating hormone increases the eumelanin: phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol. 1995;104:83-5.
11. Cesarini JP, Msika P. Photoprotection from UV-induced pigmentation and melanin introduced in sunscreens. En: Zeise L, Chedekel MR, Fitzpatrick TB, editors. Melanin: its role in human photoprotection. Overland Park: Valdenmar Publishing Company; 1995. p. 2329-44.
12. Hill HZ. The function of melanin or six blind people examine an elephant. Bioessays. 1992;14:49-56.
13. McGovern VJ. Melanoblastoma. Med J Austr. 1952:139-42.
14. Weinstock MA. Ultraviolet radiation and skin cancer: epidemiological data from the United States and Canada. En: Young ARBjörn LO, Moan J, et al, editors. Environmental UV Photobiology. New York: Plenum Press; 1993. p. 295-344.
15. Elwood JA, Johnson J. Melanoma and sun exposure. An overview of published studies. Int J Cancer. 1997;73:198-203.
16. Whiteman DC, Whiteman AC, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001;12:69-82.
17. Bataille V. Genetic epidemiology of melanoma. Eur J Cancer. 2003;39:1341-7.
18. Sturm RA. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res. 2002;12:405-16.
19. Kanetsky PA, Swoyer J, Panossian S, Holmes R, Guerry D, Rebbeck TR. A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet. 2002;70:770-5.
20. Abdel-Malek Z, Scott MC, Suzuki I, et al. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res. 2000;13 Suppl 8:156-62.
21. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet. 2001;69:765-73.
22. Smith R, Healy E, Siddiqui S, et al. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol. 1998;111:119-22.
23. Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet. 1996;5:1663-6.
24. Sturm RA, Teasdale RD, Box NF. Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene. 2001;277:49-62.
25. Schioth HB, Phillips SR, Rudzish R, Birch-Machin MA, Wikberg JE, Rees JL. Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Biochem Biophys Res Commun. 1999;260:488-91.
26. Jiménez-Cervantes C, Germer S, González P, et al. Thr40 and Met122 are new partial loss-of-function natural mutations of the human melanocortin 1 receptor. FEBS Lett. 2001;508:44-8.
27. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet. 2000;66:176-86.
28. Kennedy C, Ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol. 2001;117:294-300.
29. Bastiaens MT, Ter Huurne JA, Kielich C, et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet. 2001;68:884-94.
30. Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet. 2004;41:e13.
31. Winsey SL, Haldar NA, Marsh HP, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 2000;60:5612-6.
32. Duan Z, Shen H, Lee JE, et al. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002;11:1142-3.
33. Bertram CG, Gaut RM, Barrett JH, et al. An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype. J Invest Dermatol. 2004;122:429-32.
34. Berwick M. Epidemiology. Current trends, risk factors, and environmental concerns. En: Balch CM, Houghton AN, Sober AJ, Soong S, editors. Cutaneous melanoma. 3rd ed. St. Louis: QMP 1998; p. 551-71.
35. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer. 1995;62:377-81.
36. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15-21.
37. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903.
38. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879-87.
39. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998;16:670-82.
40. Luca M, Xie S, Gutman M, Huang S, Bar-Eli M. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene. 1995;11:1399-402.
41. Glendening JM, Flores JF, Walker GJ, et al. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res. 1995;55:5531-5.
42. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer. 1997;74:535-9.
43. Grover R, Chana JS, Wilson GD, Richman PI, Sanders R. An analysis of p16 protein expression in sporadic malignant melanoma. Melanoma Res. 1998;8:267-72.
44. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997;74:255-9.
45. Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P, Sander CA. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol. 1998;25:291-6.
46. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000;42:705-22.
47. Ruiz A, Puig S, Malvehy J, et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet. 1999;36:490-3.
48. Van der Velden PA, Sandkuijl LA, Bergman W, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 2001;69:774-9
49. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12:97-9.
50. Goldstein AM, Chidambaram A, Halpern A, et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res. 2002;12:51-5.
51. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92:713-23.
52. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene. 2001;20:5543-7.
53. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet. 2003;73:301-13.
54. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA. 1992;89:10557-61.
55. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
56. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883-5.
57. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-90.
58. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483-8.
59. Casula M, Colombino M, Satta MP, et al. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. J Clin Oncol. 2004;22:286-92.
60. Rivers JK. Is there more than one road to melanoma? Lancet. 2004;363:728-30.
61. Chin L, Merlino G, DePinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 1998;12:3467-81.
62. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47.
63. Indsto JO, Holland EA, Kefford RF, Mann GJ. 10q deletions in metastatic cutaneous melanoma. Cancer Genet Cytogenet. 1998;100:68-71.
64. Guldberg P, Thor Straten P, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57:3660-3.
65. Bergman W, Gruis NA, Sandkuijl LA, Frants RR. Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J Invest Dermatol. 1994;103:122S-5S.
66. Castellano M, Parmiani G. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res. 1999;9:421-32.
67. Ortonne JP. Photobiology and genetics of malignant melanoma. Br J Dermatol. 2002;146 Suppl 61:11-6.
68. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002;359:397-401.
69. Nagore E, Planelles MD, Ledesma E, et al. Molecular genetic analysis of HLA-DR and -DQ alleles in Spanish patients with melanoma. Acta Derm Venereol. 2002;82:90-3.
70. Bale SJ, Greene MH, Murray C, et al. Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. Int J Cancer. 1985;36:439-43.
71. López-Nevot MA, García E, Romero C, Oliva MR, Serrano S, Garrido F. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet. 1988;5:203-12.
72. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens. 1998;52:67-73.
73. Planelles D, Nagore E, Moret A, et al. HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol. 2006;154:261-6.
74. Bergman W, Watson P, De Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990;61:932-6.
75. Anderson H, Bladstrom A, Olsson H, Moller TR. Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 2000;152:1154-63.
76. Lynch HT, Brand RE, Hogg D, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical mole melanoma-pancreatic-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002;94:84-96.
77. Bataille V, Hiles R, Bishop JA. Retinoblastoma, melanoma and the atypical mole syndrome. Br J Dermatol. 1995;132:134-8.
78. Bataille V, Pinney E, Hungerford JL, Cuzick J, Bishop DT, Newton JA. Five cases of co-existent primary ocular and cutaneous melanoma. Arch Dermatol. 1993;129:198-201.
79. Azizi E, Friedman J, Pavlotsky F, et al. Familiar cutaneous malignant melanoma and tumours of the nervous system. An hereditary cancer syndrome. Cancer. 1995;1:1571-8.
80. Sun S, Pollock PM, Liu L, et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer. 1997;73:531-6.
81. Goldstein AM, Fraser MC, Struewing JP. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995;333:970-4.
82. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92:1260-6.
83. Alao JP, Mohammed MQ, Retsas S. The CDKN2A tumour suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers. Melanoma Res. 2002;12:559-63.
84. Hearle N, Humphreys J, Damato BE, et al. Role of MC1R variants in uveal melanoma. Br J Cancer. 2003;89:1961-5.
85. Vajdic C, Kricker A, Duffy DL, et al Ocular melanoma is not associated with CDKN2A or MC1R variants. Melanoma Res. 2003;13:409-13.
86. Kefford R, Bishop JN, Tucker M, et al. Genetic testing for melanoma. Lancet Oncol. 2002;3:653-4.
87. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22:3053-62.